Abstract

Deal activity in the pharmaceutical industry fell notably in 2012 as partnering strategies became increasingly focused and R&D budgets remained constrained. Mean deal values increased from 2011, however, and upfront payments remained robust as licensing continued to represent an important source of non-dilutive funding for biotech companies in a still challenging financing climate. Bolt-on acquisitions were the order of the day and some of the highest valuations were reserved for mature biotechs with late-stage or marketed products. Oncology continued to dominate the deal-making landscape and GlaxoSmithKline overtook Roche to become the most prolific dealmaker.

Copyright: © IQVIA 2018